HORSHAM, Pa. — Myonex, a global provider of integrated clinical trial supply solutions and commercial services, announced that Chief Financial Officer Greg Lavin will become Chief Executive Officer effective January 1, 2026. Lavin succeeds James Lovett, who is retiring from the role and will join the company’s board of directors to support long-term strategy.
Lavin brings extensive experience across the pharmaceutical services industry, including senior roles in clinical research organizations, preclinical and laboratory services, and healthcare data analysis. During more than six years as CFO at Myonex, he worked closely with Lovett to guide the company’s transformation from a comparator sourcing supplier to a fully integrated clinical trial supply and commercial packaging provider. Before joining Myonex, Lavin served as CFO of QPS Holdings LLC, a private equity–backed clinical research organization, where he led global post-acquisition integration efforts. He previously held financial leadership roles at SDI, Inc. and SDI Health, LLC.
“In recent years, we have evolved from a comparator sourcing to an integrated clinical trial supply solutions and commercial packaging services company, successfully weathering changes in the clinical trial landscape,” said Michael Cohen, the company’s Executive Chairman. “Greg was a driving force on that journey with us. He knows the industry, understands our clients, and shares our vision. His passion for Myonex’s opportunity in the marketplace will help build on our momentum.”
Lavin said he is honored to take on the role. “I am grateful for the opportunity to succeed James and lead Myonex into the future,” he said. “James has led Myonex through an extraordinary period of growth. I look forward to working with our teams around the world to continue to innovate patient-centric and client-first services and solutions.”
Lovett joined Myonex in 2017 and became CEO in July 2019. Under his leadership, the company opened a new 65,000-square-foot global headquarters in Horsham and launched CTRx, a patient prescription card and global pharmacy dispensing program for clinical trials. He guided several strategic acquisitions, including the clinical trial and wholesale drug business of Hubertus Apotheke in Berlin, now Myonex GmbH; SaveWay Compounding Pharmacy in Newark, Delaware; and Creapharm Bio & Pharma in France, expanding Myonex’s clinical trial, commercial packaging, distribution and bioservices capabilities.
“I would like to thank Mike Cohen for the opportunity to be a part of the Myonex story at such an exciting time in the company’s evolution,” Lovett said. “It has been a privilege to work with such a talented team of people who are so dedicated to providing innovative solutions to support their clients’ goals of developing tomorrow’s cures. Having worked with Greg for over six years, I am excited to see him lead the company toward continued growth and innovation.”
“We are grateful for the leadership James has provided to the company and for his continued efforts as a member of our Board of Directors,” Cohen said. “He leaves us in a strong position to continue on a path of growth, so that we can further expand our comprehensive suite of solutions to address the unique challenges of our clients’ clinical trials.”
